Humira biosimilars comparison
BiosimilarsCompare adalimumab biosimilars to brand Humira. Multiple biosimilars are now available, and most insurers require them before brand Humira. Products differ primarily in citrate content (injection pain), device design, and copay programs.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Humira (reference) | AbbVie | SC injection | Every 2 weeks | Original reference product; most clinical data and long-term safety experience |
| Amjevita (adalimumab-atto) | Amgen | SC injection | Every 2 weeks | Citrate-free option available; interchangeable biosimilar |
| Cyltezo (adalimumab-adbm) | Boehringer Ingelheim | SC injection | Every 2 weeks | First interchangeable adalimumab biosimilar; citrate-free |
| Hadlima (adalimumab-bwwd) | Samsung Bioepis | SC injection | Every 2 weeks | Citrate-free formulation available |
| Hyrimoz (adalimumab-adaz) | Sandoz | SC injection | Every 2 weeks | Citrate-free; available in pen and syringe |
| Yusimry (adalimumab-aqvh) | Coherus | SC injection | Every 2 weeks | Citrate-free formulation |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.